Decreased survival in patients with pancreatic cancer may be associated with an increase in histopathological expression of inflammasome marker NLRP3

• Oscar Fraile-Martinez ^[1] ; Cielo García-Montero ^[1] ; Leonel Pekarek ^[1] ; José V. Saz ^[1] ; Miguel Ángel Álvarez Mon ^[1] ; Silvestra Barrena-Blázquez ^[1] ; Natalio García-Honduvilla ^[1] ; Julia Buján ^[1] ; Ángel Asúnsolo ^[1] ; Santiago Coca ^[1] ; Melchor Alvarez-Mon ^[1] ; Luis G. Guijarro ^[2] ; Miguel A. Saez ^[1] ; Miguel A. Ortega ^[1]
  1. [1] Universidad de Alcalá

     Universidad de Alcalá

     Alcalá de Henares, España

     
  2. [2] Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain
• Localización: Histology and histopathology: cellular and molecular biology, ISSN-e 1699-5848, ISSN 0213-3911, Vol. 39, Nº. 1, 2024, págs. 35-40
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Pancreatic cancer is a malignant neoplasm that, despite its low frequency, has a 5-year survival rate of less than 10%. The study of different histopathological markers has allowed a better understanding of the onset and development of this type of tumor as well as facilitating an approach to clinical variables based on their diagnostic, prognostic, and predictive value. In this sense, the NLRP3 protein of the inflammasome has been shown to be a component of great relevance in the initiation and progression of pancreatic cancer, although the value of this biomarker in patients has not yet been clarified. In this study, we selected 41 patients with pancreatic cancer and followed them for 60 months (5 years), evaluating their NLRP3 expression using immunohistochemical techniques.

    Furthermore, by performing Kaplan-Meier curves, we evaluated the survival of these patients in relation to their NLRP3 expression. Our results show that a significant percentage of our cohort had high expression of this component (90.74%) and that there is an inverse relationship between the expression of NLRP3 and patient survival. High levels of NLRP3 expression are related to lower survival and worse prognosis in these patients, possibly due to an ineffective immune system response and increased tumor-promoted inflammation.

    Future studies should be aimed at confirming these results in larger groups and evaluating various clinical strategies based on this knowledge.